<DOC>
	<DOCNO>NCT01359449</DOCNO>
	<brief_summary>The purpose study demonstrate safety immunogenicity two dos Menactra® administer 12 18 month age concomitantly routine immunization two different provincial schedule Primary Objectives : - To describe immunogenicity Menactra® administer concomitantly routine immunization 12 18 month naïve Menjugate-primed ( MenC-primed ) infant ( measure serum bactericidal assay use baby rabbit complement [ SBA-BR ] ) - To describe immunogenicity MenC administer concomitantly routine immunization 12 month age ( measure SBA-BR ) Secondary Objectives : Safety - To describe safety profile Menactra® MenC vaccine dose give concomitantly routine immunization . Immunogenicity - To describe immunogenicity vaccine use serum bactericidal assay use human complement [ SBA-HC ] - To describe immunogenicity Pediacel administer 18 month .</brief_summary>
	<brief_title>Study Two Doses Menactra® One Dose Monovalent Meningococcal Group C Vaccine With Routine Immunizations</brief_title>
	<detailed_description>Participants depend group receive either two dos Menactra vaccine concomitantly routinely recommended vaccine one dose MenC vaccine concomitantly routinely recommended vaccine monitor safety immunogenicity . The duration subject 's participation trial approximately 7 month .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 12 month ( 365 400 day ) day inclusion Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg Informed consent form sign dated parent ( ) legally authorize representative Subject parent/legal representative able attend schedule visit comply trial procedure Group 1 : Subject receive 3 primary vaccination dose Pediacel per routine immunization schedule Group 3 : Subject receive two dos MenC vaccine approximately 2 4 month age per Alberta immunization schedule . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede first trial vaccination , except influenza vaccination ( ) , may receive least two week study vaccine Planned receipt vaccine 4 week follow trial vaccination Previous vaccination Meningococcal disease OR Subject previously receive one dose MenC vaccine , two dos MenC vaccine , two dos MenC vaccine recent dose receive past 6 month Receipt blood bloodderived product past 3 month might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Personal maternal seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C , report parent/legal representative History document invasive meningococcal disease At high risk meningococcal disease trial Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance History contraindication receipt pertussiscontaining vaccine Thrombocytopenia , report parent/legal representative , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination History seizures Chronic illness , opinion investigator , stage might interfere trial conduct completion History GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Infection</keyword>
	<keyword>Menactra®</keyword>
	<keyword>MenC</keyword>
</DOC>